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ABSTRACT
Objective: The objective of this study was to develop and validate rapid, specific, sensitive, and precise reverse-phase ultra performance liquid 
chromatography (RP-UPLC) method for the quantitative determination of grazoprevir and elbasvir, as there are no official monograph and no 
analytical method by UPLC.
Methods: Chromatographic separation was achieved on a Waters Acquity UPLC HSS C18 (2.1 mm × 100 mm, 1.8 micron) column with a 45:55 (v/v) 
mixture of 0.1% orthophosphoric acid (pH 2.8) and acetonitrile as a mobile phase, thermostated at 30°C with a short run time of 3.0 min.
Results: The retention times were 0.73 and 1.29 min for grazoprevir and elbasvir, respectively. Quantification is achieved with TUV detection at 
254 nm over the concentration range of 25–150 μg/ml for grazoprevir and for elbasvir 12.5–75 μg/ml, with a correlation coefficient of 0.999 and 
0.999, respectively. The developed method was validated according to the International Conference on Harmonization (ICH) guidelines with respect to 
linearity, accuracy, precision, specificity, and robustness. Forced degradation study was extended out under acidic, alkaline, oxidative, photolytic, and 
thermal conditions to demonstrate the stability-indicating capability of the developed UPLC method. The degradation products were well resolved 
from the main peak, thus proved the stability-indicating power of the method. The results of the analysis were validated statistically.
Conclusion: The method is precise, accurate, linear, robust, and fast. The short retention time allows the analysis of a large number of samples in a 
short period of time and, therefore, should be cost-effective for routine analysis in the pharmaceutical industry.
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INTRODUCTION
Hepatitis C virus (HCV) is a single-stranded RNA virus that is estimated 
to affect 130–150 million people worldwide [1]. HCV is a single-stranded 
RNA virus that is categorized into nine distinct genotypes. HCV infection 
has been associated with both hepatic and extrahepatic manifestations 
that increase graft loss and mortality after transplantation [2]. The 
combination of antiviral drugs grazoprevir (Fig. 1), and elbasvir (Fig. 2), 
is more effective for the treatment of patients chronically infected with 
HCV. Elbasvir/grazoprevir (Zepatier) is a combination product with an 
FDA-approved indication for the treatment of chronic HCV genotypes 
(GTs) 1 and 4 in adults [3].
Grazoprevir chemically known as (1R,18R,20R,24S,27S) -N-{(1R,2S) 
-1-[(cyclopropylsulfonyl) carbamoyl] -2-vinylcyclopropyl} -7-methoxy-
24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-
tetraazapentacyclo [24.2.1.03,12.05,10.0,18,20] nonacosa-3,5,7,9,11-
Benton-27-carboxamide is a direct acting antiviral medication used as 
a part of combination therapy to treat chronic hepatitis C, an infectious 
liver disease caused by infection with HCV. It is a protease inhibitor of 
HCV NS3/4A that prevents cleavage of the poly protein necessary for 
replication [4,5].
Elbasvir chemically known as dimethyl N,N’-([(6S)-6H-indolo[1,2-c]
[1,3]benzoxazine-3,10-diyl]bis{1H-imidazole-5,2-diyl-(2S)-
pyrrolidine-2,1-diyl[(2S)-1-oxo-3-methylbutane-1,2-diyl]})
biscarbamate is a NS5A inhibitor, preventing hepatitis C viral RNA 
replication and virion assembly [6]. Elbasvir is a drug approved by the 
FDA for the treatment of Hepatitis C.
The literature survey revealed that there are a very few analytical 
methods [7-10] reported for the determination of elbasvir in single 
and in combination with grazoprevir. Referable to the deficiency of 
reported ultra performance liquid chromatography (UPLC) methods 
describing determination of the mixtures under investigation, it was 
deemed useful to produce simple, sensitive, and selective reverse-phase 
UPLC (RP-UPLC) method that could be useful for the simultaneous 
determination of grazoprevir and elbasvir. The suggested method was 
designed to be suitable for the quality assessment of these mixes in 
a tablet dosage form. The proposed method was validated as per the 
guidelines suggested by ICH [11].
METHODS
Instruments and apparatus
The Acquity waters UPLC system equipped with TUV detector and 
autosampler integrated with Empower Software was used to perform 
development and validation of the method. A Acquity HSS C18, 
100 mm × 2.1 mm, a column with particle size of 1.8 μm was used as a 
stationary phase for chromatographic separation and determination of 
grazoprevir and elbasvir. Sartorius analytical balance was used for all 
weighings, Metsar pH meter was used for the pH measurement of buffer 
solution, and Labman Sonicator was used to dissolve the standard and 
samples.
Materials
Working standards of grazoprevir and elbasvir were gifted by spectrum 
laboratories  (Hyderabad,  India).  Dosage  form  ZEPATIER  tablets 
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orthophosphoric acid (OPA) purchased from Merck Ltd, Mumbai, India, 
were used in the study.
Preparation of solutions
Preparation of standard stock solutions
Accurately weighed 10 mg of grazoprevir and 5 mg of elbasvir 
transferred to 10 ml of volumetric flasks separately. 8 ml of diluent was 
added to both of these flasks and sonicated for 10 min. Flasks were 
made up with diluents and labeled as standard stock solution 1 and 
2 (1000 µg/ml of grazoprevir and 500 µg/ml of elbasvir).
Preparation of standard working solution (100% solutions)
About 1 ml of each stock solution was pipetted out and taken into a 
10  ml  volumetric  flask  and  made  up  with  diluents  (100  µg/ml  of 
grazoprevir and 50 µg/ml of elbasvir).
Preparation of marketing sample stock solution
A total of 10 tablets were weighed and the average weight of each 
tablet was calculated, then, the weight equivalent to one tablet was 
transferred into a 10 ml volumetric flask, 8 ml of diluent was added 
and sonicated for 25 min, further, the volume was made up with 
diluent  and  filtered  by UPLC  filters  (1000  µg/ml  of  grazoprevir  and 
500 μg/ml of elbasvir).
Preparation of sample working solution (100 % solution)





about 100 ml of Milli-Q water, and final volume makes up to 1000 ml 
with mill-Q water. Buffer pH adjusted to 2.8 with triethylamine.
Diluent
Based on the solubility of the drugs, diluent was selected, acetonitrile 
and water taken in the ratio of 50:50.
Method development
Chromatography
Chromatographic analysis was performed on Acquity UPLC HSS 
C18 (2.1 mm × 100 mm, 1.8 micron). The mobile phase consists of 
0.1% OPA (pH 2.8) buffer:acetonitrile (45:55 v/v) was used throughout 
the analysis. The  flow rate was 0.3 ml/min,  the  injection volume was 
1.0 μl, column temperature was 30°C, run time 3 min, and detection was 
performed at 254 nm using a TUV detector.
Calibration curve of grazoprevir
Aliquots of working standard solution (100 μg/ml) of grazoprevir (0.25, 
0.5, 0.75, 1, 1.25, and 1.5 ml) were transferred into a series of 10 ml 
volumetric flasks and volume was adjusted to the mark with diluents 
to  get  concentrations 25,  50,  75,  100,  125,  and 150 μg/ml.  Solutions 
were injected into the system with stated chromatographic conditions. 
The graph of area of peak obtained versus respective concentration was 
plotted. The mean area and its standard deviation were calculated.
Calibration curve of elbasvir
Aliquots  of  working  standard  solution  (50  μg/ml)  of  elbasvir  (0.25, 
0.5, 0.75, 1, 1.25, and 1.5 ml) were transferred into a series of 10 ml 
volumetric flasks and volume was adjusted to the mark with diluent 
to get concentrations 12.5, 25, 37.5, 50, 62.5, and 75 μg/ml. Solutions 
were injected into the system with stated chromatographic conditions. 
The graph of area of peak obtained versus respective concentration was 
plotted. The mean area and its standard deviation were calculated.
Method validation
System suitability parameters
The system suitability parameters were determined by preparing 
standard solutions of grazoprevir (100 μg/ml) and elbasvir (50 μg/ml), 
and the solutions were injected 6 times and the parameters such as 
peak tailing, resolution, and USP plate count were determined.
Linearity
Linearity was demonstrated from 25% to 150% of standard 
concentration using minimum six calibration levels (25%, 50%, 75%, 
100%, 125%, and 150%) for both the title drugs. The method of linear 
regression was used for data evaluation.
Accuracy
The accuracy of an analytical method expresses the nearness between 
the reference value and found value. The accuracy of the method was 
measured in triplicate at three concentration levels, i.e., 50%, 100%, 
and 150% of standard solutions of grazoprevir and elbasvir [12-14].
Limit of detection (LOD) and limit of quantitation (LOQ)
Increasingly, dilute solution of each drug was injected into the 
chromatograph and signal-to-noise (S/N) ratio was calculated at each 
concentration. The LOD and LOQ were calculated on the basis of signal-
to-noise ratio of 3:1 and 10:1, respectively.
Robustness
Robustness of the method was determined to ensure its capacity 
to remain unaffected by small deliberate variation in the method 
parameters such as a mobile phase ratio, temperature of the column, 
and flow rate of the mobile phase [15,16].
Forced degradation studies
A thorough verification of method selectivity was carried out by forcing 
degradation studies, also known as stress testing. They are performed 
to determine possible degradation products and confirm the ability of 
the developed method to detect and separate impurities, which can 
possibly arise during the lifetime of an API or drug product. Stress 
tests are conducted in conditions exceeding those used in accelerated 
stability testing. Stress studies were performed under conditions 
of dry heat (thermal studies), hydrolysis (in the presence of acidic, 
alkaline, and water), oxidation, and photolysis. A minimum of four 
samples was generated for every stress condition, the blank solution 
Fig. 1: Grazoprevir structure
Fig. 2: Elbasvir structure
102
Asian J Pharm Clin Res, Vol 11, Issue 4, 2018, 100-104
 Madhavi and Rani 
stored under normal conditions. 100% sample solution subjected to 
stress treatment. Hydrolytic decomposition of grazoprevir and elbasvir 
was conducted at 30°C in 2 N HCl, water, and 2 N NaOH. For oxidative 
stress studies, sample was dissolved in 20% H2O2 and kept for 1 day 
at room temperature. A photolytic study, drug solution was exposed to 
ultraviolet light for 1 day [17].
RESULTS
System suitability
The column efficiency, resolution, and peak symmetry were calculated 
for the standard solutions. The retention time of grazoprevir and elbasvir 
was found to be 0.72 and 1.28 min, respectively. The peaks obtained for 
grazoprevir and elbasvir were sharp and have clear baseline separation 
(Fig. 3). It was observed from the results that the system suitability 
parameters meet the requirement of method validation. System 
suitability and method validation results are summarized in Table 1.
Linearity
The calibration curves plotted for grazoprevir and elbasvir were 
linear  over  the  concentration  range  of  25–150  µg/ml  for  grazoprevir, 
12.5–75  µg/ml  for  elbasvir.  Peak  areas  were  plotted  against 
concentrations and linear regression analysis performed for the resultant 
curve (Figs. 4 and 5). The correlation coefficient values of grazoprevir 
and elbasvir are 0.999 and 0.999, thus indicating excellent correlation 
between peak areas and concentrations of the analyte. The results are 
summarized in Table 2.
Precision
The precision of an analytical method gives information on the random 
error. It expresses of agreement between a series of measurements 
obtained from multiple sampling of the same homogeneous sample under 
prescribed conditions. The proposed method was evaluated by studying 
the precision as percentage relative standard deviation (% RSD). The 
% RSD was found to be less than 2 for all the drugs, which indicate that 
the method is precise. Data on the relative retention times obtained in a 
series of four consecutive injections also showed acceptable repeatability 
when analyzed not only on the same day but also on the 2nd day. This is 
confirming good precision of the method.
Table 1: Results from system suitability studies and validation
Parameter Grazoprevir Elbasvir
Theoretical plates 4589 9546
K prime (retention factor) 6.28 11.93
Tailing factor 1.86 1.55
Linearity (r2) 0.999 0.999
% RSD for accuracy 0.88** 0.92**
% RSD for repeatability and intraday 
precision
0.9* and 0.8* 0.9* and 0.7*
LOD 0.20 µg/ml 0.13 µg/ml
LOQ 0.62 g/ml 0.39 µg/ml
*Results are mean of six injections. **Results are mean of three injections, 
LOD: Limit of detection, LOQ: Limit of quantitation
Table 2: Linearity data for grazoprevir and elbasvir
% Level (approx) Grazoprevir Elbasvir
Concentration (μg/ml) Peak area Concentration (μg/ml) Peak area
25 25 172958 12.5 69748
50 50 308953 25 140597
75 75 456108 37.5 208627
100 100 592958 50 274082
125 125 728638 62.5 348669
150 150 878708 75 411259
Slope 5759.3 5500.3
Intercept 16387 1308
Table 3: Robustness data for grazoprevir and elbasvir
Condition Grazoprevir Elbasvir 
RT Peak area % RSD RT Peak area % RSD
Flow rate (−) 0.2 ml/min 0.81 701762 0.8 1.49 328367 1.3
Flow rate (+) 0.4 ml/min 0.65 225665 0.8 1.14 225665 0.8
Mobile phase (−) 40B: 60A 0.71 524490 0.6 1.20 234585 0.6
Mobile phase (+) 50B: 60A 0.71 522215 0.5 1.31 233907 0.4
Temp (−) 25°C 0.71 520713 0.5 1.31 231380 0.9
Temp (+) 35°C 0.72 553682 0.7 1.30 246118 1.1
Fig. 3: Ultra performance liquid chromatography chromatogram 
of standard















Fig. 4: Linearity curve for grazoprevir
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Accuracy
The accuracy of the proposed method was determined by analyzing 
grazoprevir and elbasvir samples spiked at three different concentration 
levels in triplicate. To find out the accuracy, a known amount of standard 
drug was added to the fixed amount of preanalyzed sample solution at 
three different concentration levels in triplicate. Percent recovery of 
the drugs was calculated by comparing the area before and after the 
addition of the standard drug. Percent recovery of grazoprevir ranged 
from 98.15% to 100.88% and for elbasvir 98.36–101.03% showing 






No significant effect was observed on system suitability parameters 
such as theoretical plates, purity angle, and purity threshold when small 
but deliberate changes were made for chromatography conditions such 
as change in flow rate (±5%), temperature (±5%), and organic content 
(±2%). The results are summarized in Table 3.
Forced degradation studies
The specificity of the method was also evaluated by the forced 
degradation study. The peak purity angle is smaller than that of peak 
threshold angle means there was no interface with the analyte peak 
from degradation products. Major degradation occurred for grazoprevir 
and elbasvir under acid hydrolysis condition up to 5% and 4.81%, 
respectively. The results are summarized in Table.4.
Assay
The validated method was applied for the determination of grazoprevir 
and elbasvir in commercially available ZEPATIER tablets. The results of 
the assay (n=3) undertaken yielded 99.69% (% RSD = 0.47) of grazoprevir 
and 98.85% (% RSD = 0.61) of elbasvir. The data are given in Table 5.
DISCUSSION
The present study was aimed at developing a precise, sensitive, 
rapid, and accurate UPLC method for the analysis of grazoprevir and 
elbasvir in bulk drug and in pharmaceutical dosage form. Developing 
a UPLC method was to reduce the run time of the method and solvent 
consumption for routine analysis such as assay, dissolution, and 
content uniformity during quality assurance. The author developed 
stability indicating RP-UPLC method and validated for simultaneous 
estimation of grazoprevir and elbasvir in bulk and tablet dosage form 
using Acquity UPLC HSS C18 (100 × 2.1 mm, 1.8 mm). The mobile 
phase consists of 0.1% OPA buffer: Acetonitrile (45:55 v/v) was used 
throughout  the  analysis.  The  flow  rate was 0.3 ml/min,  the  injection 
volume was 1.0 μl, column temperature was 30°C, run time 3 min, and 
detection was performed at 254 nm using a TUV detector. The retention 
time of grazoprevir and elbasvir was found to be 0.73 and 1.29 min, 
respectively. The linearity was found satisfactory in the range of 
25–150 µg/ml and 12.5–75 µg/ml for grazoprevir and elbasvir showed 
good correlation coefficient values 0.999 and 0.999, respectively. Less 
% RSD values showed the good precision and accuracy of the method. 















Fig. 5: Linearity curve for elbasvir
Table 4: Degradation data of grazoprevir and elbasvir
Type of degradation Grazoprevir Elbasvir
Area % Recovered % Degraded Area % Recovered % Degraded
Acid 566244 95.00 5.00 262482 95.19 4.81
Base 580458 97.38 2.62 267861 97.14 2.86
Peroxide 586306 98.36 1.64 271028 98.29 1.71
Thermal 590308 99.03 0.97 274131 99.42 0.58
UV 591869 99.29 0.71 273416 99.16 0.84
Water 592662 99.43 0.57 273398 99.15 0.85





% RSD % Assay
Grazoprevir 100 99.69 0.47 99.69
Elbasvir 50 49.42 0.61 98.85
Fig. 6: Ultra performance liquid chromatography chromatogram for 
limit of detection of grazoprevir and elbasvir
Fig. 7: Ultra performance liquid chromatography chromatogram for 
limit of quantitation of grazoprevir and elbasvir
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The results obtained by the forced degradation studies were good 
enough to say that developed method was stable. The comparison of 
the developed method with published methods shows the developed 
method is new simple, rapid, robust, and economical method.
CONCLUSION
A rapid and robust method for the analysis of grazoprevir and elbasvir 
was developed and its applicability as a method for analyzing stability 
was checked. The method was found to be specific, accurate, precise, 
and reproducible. Force degradation studies confirmed its ability to 
determine stability because no interference from degradation products 
was observed. Moreover, no influence from excipients was found, 
allowing it to be used in the final drug product analysis. The method 
was also validated in accordance with ICH requirements.
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